Subscribe to our Newsletters !!
The life cycle of malaria is a complex process inv
Because the labs are equipped for doing research,
Relevant codes should be used when coding fibromya
New literature from Copley Scientific, the worldâ€
Principal Component Analysis (PCA) is a powerful t
It is important to understand that natural remedie
In our cover story, we shine a spotlight on The Magazine
Sun Pharmaceutical Industries Limited announced on Thursday that it would purchase Concert Pharmaceuticals of the United States for $576 million in cash in order to gain access to an investigational medication for the treatment of patchy baldness.
Deuruxolitinib, the top contender for Concert, is being studied as a treatment for the autoimmune disorder alopecia areata, which causes patchy hair loss.
Sun Pharma of India said that it will start a tender offer to buy Concert at $8 per share, a premium of 16% over the stock’s most recent finish.
Additionally, contingent value rights will be given to Concert stockholders, entitling them to an extra sum of up to $3.50 per share of common stock in cash, subject to certain sales milestones.